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Abstract
Lymphangioleiomyomatosis (LAM) is a rare lung disease affecting almost exclusively women, characterized by 
the invasion and abnormal proliferation of smooth muscle-like cells in pulmonary parenchyma and axial lymphatics. 
LAM cells bear mutations in Tuberous Sclerosis Complex (TSC) genes. It has been hypothesized that uterus might 
be the primary site of origin and one of the most frequent metastatic or disseminated site of LAM cells. We developed 
a mouse model to study the migratory and invasive properties of human LAM/TSC cells to the uterus. We also 
examined the action of rapamycin and anti-Epidermal Growth Factor Receptor (EGFR) antibody.
LAM/TSC cells were endonasally administered to 3 week old immunodeficient female nude mice. 5 months later 
mice were divided in 4 groups: control, LAM/TSC cell-administered mice, LAM/TSC cell-administered mice treated 
with rapamycin, and LAM/TSC cell-administered mice treated with anti-EGFR antibody. Drugs were administered for 
one months. Uteri were analysed for the presence of human LAM/TSC cells by COX IV antibody, lymphangiogenesis 
by LYVE 1 expression and angiogenesis by counting blood vessels. 
LAM/TSC cells migrated to the uterus without causing any morphological lesion. Interestingly, LAM/TSC cells 
increased the number of blood vessels while did not cause any alteration in lymphatics vessels. Anti-EGFR antibody 
and rapamycin reduced the number of human LAM/TSC and counteracted the proliferation of blood vessels in 
uteri. Although both drugs did not change the expression of LYVE 1, localization of lymphatics was mainly in the 
perimetrium after drug treatment.
Our data describe the strong invasive capability of human LAM/TSC cells which migrated to the uterus. LAM/
TSC cells presence is accompanied by increased angiogenesis. Anti-EGFR antibody and rapamycin were effective 
in reducing the LAM/TSC cell number and blood vessel proliferation.
Keywords: Lymphangioleiomyomatosis; Tuberous sclerosis 
complex; Migration; Uterus; Tuberin-null cells; Mouse model 
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Introduction
Lymphangioleiomyomatosis (LAM) is a rare progressive lung 
disease that affects almost exclusively women of childbearing age [1]. 
LAM can be sporadic or associated to Tuberous Sclerosis Complex 
(TSC), an autosomal dominant syndrome caused by mutations 
in TSC1 or TSC2 genes which encode hamartin and tuberin [2,3]. 
Hamartin and tuberin form heterodimers that inhibit the small 
GTPase Ras homologue enriched in brain (Rheb) [4]. The activation 
of Rheb leads to the activation of mammalian Target of Rapamycin 
(mTOR) complex 1 (TORC1) which controls protein translation, cell 
size, and cell proliferation [5,6]. The loss of tuberin or hamartin causes 
hyperactivation of mTORC1, which has been observed in TSC and LAM 
cells. LAM is characterized by proliferation of abnormal neoplastic 
smooth muscle cells (LAM cells) leading to lymphatic abnormalities, 
cystic formation in lung parenchyma, pneumothorax, and progressive 
pulmonary failure [7,8]. It is not clear whether uterine lesions, such 
as leiomyomas, are common manifestations in LAM and there are 
lacking informations regarding gynecologic pathology in LAM [9,10]. 
However, the female predominance of LAM, the reports of symptom 
mitigation in LAM patients after oophorectomy and worsening of 
symptoms during pregnancy suggests that estrogen may promote 
the metastasis of tuberin-null cells [11]. Moreover, uterus or adjacent 
areas in the retroperitoneum or pelvic cavity have been proposed as 
the primary site of origin of LAM [7]. LAM cells behave as cancer 
cells in term of growth, proliferation, cell survival in the circulation 
and metastasis [12,13]. Despite their apparently benign morphology, 
LAM cells exhibit metastatic properties that can be attributed to the 
modification caused by impaired TSC1 or TSC2 functionality [14]. 
Moreover, cells bearing loss of heterozigosity for TSC genes have been 
isolated from blood of sporadic LAM patients supporting, besides 
a common origin for the two diseases, the metastatic spread among 
organs [13]. 
We have isolated LAM/TSC cells from chylous thorax of a patient 
affected by LAM associated to TSC, bearing a germline TSC2 mutation 
and an epigenetic defect causing the absence of tuberin [15]. The 
proliferation of these LAM/TSC cells is Epidermal Growth Factor 
(EGF)-dependent and blockade of EGF receptor causes cell death as we 
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previously showed in other human cells lacking-tuberin purified from 
angiomyolipomas, such as the TSC2-/- and TSC-/meth ASM cells [16-18]. 
Differently, rapamycin, the specific inhibitor of mTOR, blocks the 
proliferation of LAM/TSC cells indicating a heterogeneous capability 
to affect TSC2-deficient cell proliferation. LAM/TSC cells display also 
the ability to survive independently from adhesion, show an extremely 
low proliferation rate in nonadherent condition consistent with 
tumour stem cell characteristics and bear characteristics of stemness 
thus all together these properties suggest that LAM/TSC cells might 
have strong invasive features. We developed a mouse model aimed 
at understanding such characteristics where were administered 
endonasally to nude mice. There we report that LAM/TSC cells 
migrate through the lymphatic and blood systems, reach the uterus 
and colonize. Moreover to test therapeutic approaches, we evaluated 
the effect of anti-EGFR antibody and rapamycin. 
Materials and Methods 
Cell culture
LAM/TSC cells were obtained from chylous effusion of a female 
patient affected by LAM associated to TSC and isolated, characterized 
and grown as previously described [15]. LAM/TSC patient who had 
given written informed consent according to the Declaration of 
Helsinki. The study was approved by the Institutional Review Board 
of Milan’s San Paolo Hospital. The cells were maintained in culture 
medium contained a 50/50 mixture of DMEM/ Ham F12 (Euroclone, 
Paignton, UK) supplemented with 200 nmol/L hydrocortisone (Sigma-
Aldrich, St. Louis, MO), 10 ng/mL epidermal growth factor (EGF; 
Sigma-Aldrich), 1.6 mol/L ferrous sulfate (Sigma-Aldrich), and 15% 
fetal bovine serum (Euroclone) in a humified incubator in 5% CO2 at 
37°C. LAM/TSC cells were used at 15 to 20 passages. As previously 
reported, these cells can be grown as a stabilized cell line and were 
checked routinely for morphological, biochemical, and genetic features. 
Animal experiments and pharmacological treatments
Immunodeficient female nude mice nu/nu Hsd: athymic were 
obtained from Harlan Laboratories (Udine, Italy). Mice were housed 
in individual plastic cages under controlled conditions (temperature 
22-23°C with light/dark cycle of 12h). All experimental procedures 
were performed in accordance with the Italian Guidelines for 
Laboratory Animals, which conforms to the European Committees 
Directive of November 1986 (86/609/EEC), and study protocols were 
previously approved by the Ministero della Sanità (2/2011 Protocol). 
After light anesthesia by intramuscular injection of 4% chloral 
hydrate, 2x105 LAM/TSC cells were endonasally administered to each 
immunodeficient female nude mouse (3 weeks old) using a microtip 
and allowing the mice to breath the drop (25 µl) of physiological 
solution (0.9% NaCl) containing the cells. At 5 months post endonasal 
cell administration, mice were randomly divided into four different 
groups: (a) LAM/TSC mice, (b) LAM/TSC mice treated with anti-
EGFR antibody (Merck, Darmstadt, Germany), (c) LAM/TSC mice 
treated with 4 mg/kg rapamycin (Rapamune-Sirolimus; Wyeth 
Europe, Maidenhead, UK) (d) WT control mice, treated with the 
vehicle. Drugs were administrated intraperitoneally (i.p) twice 
weekly for 1 month. Anti-EGFR antibody was administrated at 
a starting dose of 400 mg/m2 followed by a subsequent dose of 250 
mg/m2 and rapamycin was administrated at 4 mg/kg. 3 or 6 months 
after endonasal administration mice were sacrificed under 4% chloral 
hydrate anesthesia. Uteri were excised, fixed in 4% paraformaldehyde 
at 4°C overnight and embedded in paraffin.
Histology
8 μm thick sections from paraffin-embedded samples were stained 
with hematoxylin and eosin for histological analysis. Images of uterus 
tissue sections were acquired with LEICA DM4000 B microscope (Leica 
microsystems GmbH, Wetzlar, Germany) under X20 magnification. 
Blood vessels were hand-counted by three independent observers 
under light microscope (X20) in hematoxyl-eosin nonconsecutive 
sections. The results were expressed as the mean number of vessels per 
fields in each group [19,20].
Immunohistochemical analysis
Immunohistochemical analysis was performed according to the 
staining procedure provided by ABC-AP Vector Laboratories kit 
(Vector Laboratories, Burlingame, CA). Sections were deparaffinized, 
rehydrated through a graded ethanol series and heated to 95°C for 20 
minutes in citrate buffer (pH 6.0) for antigen retrieval. After cooling to 
room temperature, sections were incubated with 0.3% H2O2/methanol 
for 20 minutes to quench endogenous peroxidase activity and blocked 
in 3% bovine serum albumin/TBS solution at room temperature 
for 2 hours. Subsequently, the slides were incubated overnight at 
4°C in a moist chamber with primary antibody rabbit monoclonal 
antibody anti-COX IV (3E11), reactive with human-specific COX 
IV, the terminal enzyme complex in the respiratory chain localized 
to the inner mithocondrial membrane (Cell Signaling Technology, 
Beverly, MA; 1:350 dilution) [21] and then with the biotinylated rabbit 
secondary antibody (1:100; Pierce, Rockford, IL, USA). The bound 
secondary antibody was amplified with ABC-AP Vector Laboratories. 
Vector Red substrate was used for color development and nuclei 
were counterstained with Mayer’s hematoxylin, For quantification of 
TSC2 human cells in uteri, the number of COX IV positive cells was 
calculated in 6 field for each group at X40 magnification. The results 
were expressed as ratio of n° positive/(n° total x 10-3) cells.
Immunofluorescence analysis 
Sections were blocked with 3% bovine serum albumin/TBS at 
room temperature for 2 hours and incubated overnight at 4°C in a 
moist chamber with goat polyclonal antibody LYVE 1 (R&D System, 
Minneapolis, MN, USA; 5 μg/mL). Staining was revealed with goat 
secondary antibody Alexa Fluor 488-conjugated (Molecular Probes; 
Invitrogen, Paisley UK; 1:200 dilution). Nuclei were stained with 2 μg/
mL DAPI (Sigma-Aldrich). Samples were analyzed using a fluorescence 
microscope (LEICA 4000B). Lymphatic Vessels Density (LVD) was 
quantified using Lymphatic Vessel Analysis Protocol (LVAP) plug-
in for ImageJ software (National Institutes of Health, Bethesda, MD; 
available at http://rsb.info.nih.gov/ij/index. Html).
Statistical analysis
Statistical analyses were carried out by Student’s t-test or one-way 
ANOVA analysis as appropriate to determine differences between 
experimental groups.  All data were expressed as mean ± SEM. In all 
cases, P values less than 0.05 were considered statistically significant. 
Analysis was performed with the GraphPad Prism 5 (version 5, 
GraphPad software, Inc., San Diego, CA).
Results
Invasion of uterus by LAM/TSC cells 
The capability of LAM/TSC cells to invade uterus was studied 
in vivo by administrating the cells to 3 week old female nude mice 
when the mice have not yet reached the sexual maturation to allow 
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them to better invade organs. No macroscopic uterine alterations were 
observed at 3, or 6 months after LAM/TSC cell administration (data 
not shown). Indeed, 3 and 6 months after cell inhalation, human LAM/
TSC cells were detected in the myometrium of mice uteri (Figure 1A). 
Here we showed that the human cells were detected 3 and 6 months 
after cell administration, by immunoreactivity to COX IV antibody. No 
aggregation in cluster formations was observed. Number of human cells in 
uteri at 3 and 6 months from LAM/TSC cell administration was 2.6 ± 1.2 
and 3.9 ± 0.66 cells/(n° total cells x 10-3), respectively (Figure 1B). 
Anti-EGFR antibody and rapamycin action on LAM/TSC 
cells in uterus 
We recently reported that LAM/TSC proliferation is blocked by 
rapamycin and anti-EGFR antibody administration that also causes 
cell death [15]. The effect of the two drugs on these cells migrated to 
the uterus. The quantitative and qualitative evaluations of the action 
of the two agents show that both significantly reduced their number 
(Figure 2).
Effect of anti-EGFR Ab and rapamycin on angiogenesis and 
lymphangiogenesis caused by LAM/TSC cell administration 
in uteri
Six months after LAM/TSC cell administration, numerous blood 
vessels were observed in mice uteri indicating a specific ability of LAM/
TSC cells to cause angiogenesis (Figure 2A). Both, anti-EGFR Ab and 
rapamycin reduced the number of blood vessels as demonstrated 
quantitatively by assessing the number of blood vessels per fields 
(Figure 3A and B). 
Lymphatic involvement in human LAM has been demonstrated 
by the observation of higher number of lymphatics in the lungs and 
LAM lesions, and in mice lungs after inoculation of TSC2-/- ASM cells 
[22,23]. However, after LAM/TSC administration immunoreactivity to 
LYVE 1, a well known lymphatic capillary marker and lymph-specific 
receptor for hyaluronan, was unchanged in uterus (Figure 4A) [24]. 
Lymphatic Vessel Density (LVD) based on LYVE 1 staining was not 
increased by LAM/TSC cell administration and the treatments with 
anti-EGFR antibody and rapamycin did not change it (Figure 4A 
and B). In control and LAM/TSC cell-administered mice, lymphatic 
vessels were observed in the connective tissue or stroma between the 
longitudinal and circular muscle layers of the myometrium while after 
treatment with rapamycin or anti-EGFR antibody LYVE 1 positivity 
was almost exclusively localized in the perimetrium (Figure 4A). 
Discussion
LAM is associated with the metastasis of histopathologically 
benign TSC1 or TSC2-deficient cells and has a very strong gender 
predisposition. LAM is a neoplasm arising from constitutive activation 
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Figure 1:  Immunohistochemical detection of human LAM/TSC cells by using 
COX IV rabbit monoclonal antibody (red staining) in uteri of mice 3 (A) and 6 
(B) months after human LAM/TSC cell administration. COX IV positive cells 
(arrows) are detected in the myometrium layer (X40). Scale bars: 50 µm. 
Quantification of LAM/TSC cells in uteri was calculated as percentage of COX 
IV-labelled LAM/TSC cells/ total number of cells in the field (C). Data are 
expressed as mean ± SEM. *P<0.05 vs n°COX IV labelled cells/ (n°total cells 
x10-3) of mice 3 months after LAM/TSC cell administration
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Figure 2:  Immunohistochemical detection of human LAM/TSC cells in uteri 
and anti-EGFR anitbody and rapamycin effect : detection of LAM/TSC cells 
by using COX IV rabbit monoclonal antibody (red staining) in uteri of mice 6 
months after LAM/TSC cell administration (A), in LAM/TSC cell–administered 
mice treated with anti-EGFR antibody (B), and in LAM/TSC cell-administered 
mice treated with rapamycin (C) (X40).  Scale bars: 50 µm. Quantification of 
LAM/TSC cells in uteri was calculated as percentage of COX IV-labelled LAM/
TSC cells on the total number of cells in the field (D). ***P<0.001, vs n° of COX 
IV labelled cells in LAM/TSC cell-administrated mice.
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Figure 3: Analysis of angiogenesis following staining with hematoxylin 
and eosin in uteri of control nude mice (A), 6 months after LAM/TSC cell 
administration (B), following treatment with anti-EGFR Ab (C) or rapamycin 
(D). Representative images are shown (H&E X20). Scale bars: 100 µm. 
Quantification was done by counting the number of blood vessels in a field 
(6 fields for 8 mice for each group) as described in Material and Methods (E). 
Data are expressed as mean ± SEM. **P<0.01 vs control mice. ##P<0.01 vs 
LAM/TSC-cell administered mice.
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of the mTOR signaling pathway dysregulated by a functional loss of 
TSC genes [2,3]. Our group has contributed to elucidate some of the 
properties of human TSC and LAM cells including the role of epigenetic 
modification in causing the loss of heterozigosity, their metastatic 
properties described in a LAM model and the specific pharmacological 
actions of agents such rapamycin, anti-EGFR antibody and rosuvastatin 
[15-18,25,26]. 
Recently, the generation of a variety of mouse models by the 
injection of TSC2-deficient cells in specific conditions has given new 
input to study the invasive features of TSC2-deficient cells providing 
useful systems for in vivo drug testing [23,27,28]. We previously 
reported the development of an animal model of LAM through the 
endonasal administration of human TSC2-/- ASM cells that infiltrate 
lymph nodes and lungs with consequent enlargement of the alveolar 
spaces [23]. Rapamycin and, more specifically, anti-EGFR antibody 
counteract these pulmonary lesions caused by the administration of 
TSC2-/-ASM cells. Here we report that also the uterus may represent a 
target for LAM cells. 
LAM/TSC cells were isolated from chylous thorax of a patient 
affected by LAM associated to TSC, in vitro display the ability to survive 
in adherent and nonadherent conditions and bear EMT features [5]. 
In our opinion these characteristics may help to give new insights 
to study the migratory ability of LAM cells in vivo and to evaluate 
pharmacological treatments. 
LAM is a pulmonary disease characterized by abnormal 
proliferation of smooth muscle-like cells in the lungs and along the 
axial lymphatic system. Extra pulmonary LAM has major locations 
in the mediastinum, in the upper retroperitoneal areas close to 
the abdominal aorta, and the pelvic cavity [29]. However it is still 
unclear how often the uterus is also affected in patients with LAM. 
Hayashi et al. reported that women with pulmonary sporadic LAM 
and TSC-LAM are commonly affected by lesions in genital organs, 
most frequently within the uterus including diffuse leiomyomatosis, 
benign metastasizing leiomyoma, epithelial leiomyosarcoma, and 
endometrial stromal sarcoma [9]. On the other hand, another study 
demonstrated that uterine leiomyomas are not more common in LAM 
than in the general population [10]. However, the use of hysterectomy 
and oophorectomy in LAM has a high frequency. The mechanism 
for the development of uterine LAM remains unclear. An important 
involvement of uterus in LAM is supported by the hypothesis that the 
uterus may be one of the most frequent metastatic or disseminated 
sites of LAM and the chance that uterus might be the primary site 
of origin of LAM cells. Indeed, in a less aggressive rare lung disease, 
called benign metastasizing leiomyoma, it is well known that 
uterine leiomyomas metastasize to the lungs [30]. Human LAM/
TSC cells survived and migrated to uteri, and were detected 
3 and 6 months after cell administration confirming in vivo 
the strong invasive properties of LAM cells. LAM/TSC cells were 
administered to 3 week old female nude mice to allow to the cells to 
invade during mice sexual maturation and to better resemble the LAM 
features such as the frequent onset at the beginning of the childbearing 
years. Human cells did not form clusters even if their number was 
higher at 6 months after cell administration. The metastatic potential 
of LAM cells is demonstrated by the presence of LAM cells in blood 
and lymphatic vessels, the evidence of LAM recurrence in transplanted 
lungs of recipients and the finding of identical TSC2 mutations in 
lung LAM cells and renal angiomyolipoma cells of patients with 
sporadic LAM [3,13,31]. Our data support the concept that LAM is 
associated with metastasis of histologically benign TSC2-deficient 
cells. In our animal model we did not observed any macroscopic and 
morphological lesions in uteri. This might be ascribed to the small 
number of LAM/TSC cells that reached the uterus, and otherwise to the 
healthy condition of the animal. Changing the route of administration, 
such as intraperitoneal or subcutaneous administration, might give a 
more effective invasion. It is also possible that in a healthy mouse a 
hormone administration might be needed to enhance uterine lesions as 
it occurs in LAM progression where estrogen have a specific role [11]. 
LAM progression is enhanced in women during the reproductive years 
and estradiol promotes LAM cell proliferation and likely metastasis 
in vivo indicating an important role of estrogens in LAM [11]. Lung 
LAM lesions share many features with uterine leiomyomas such as 
similar appearing smooth muscle cells, expression of estrogen and 
progesterone receptors and proliferative sensitivity to estrogens. The 
fact that uterine leiomyomas may be related to a genetic TSC defect is 
demonstrated by the development  of spontaneous uterine leiomyomas 
in Eker rat model with high frequency [32]. Eker rats carry a germline 
mutation in the rat homologue of the TSC2 gene demonstrating that 
the genetic defect in TSC confers susceptibility to uterine leiomyoma 
[32]. Likewise, a uterine-specific Tsc-2 knockout mouse develops 
myometrial proliferation and uterine leiomyomas with progressive 
uterine enlargement both prevented by ovariecomy [30]. Myometrial 
Tsc2 null tumors were found in the lungs suggesting the ability of Tsc2 
null myometrial cells to migrate from the uterus to the lungs.
Rapamycin and anti-EGFR antibody treatment significantly 
reduced the number of LAM/TSC cells in uteri. Rapamycin has been 
shown to stabilize the lung function of LAM patients and to promote 
the regression of TSC angiomyolipomas which tended to increase 
again once the therapy was discontinued [33-35]. Anti-EGFR antibody 
is efficacious in treating several types of cancer such as colorectal and 
head-and-neck cancers [36]. We previously showed that anti-EGFR 
antibody more efficiently than rapamycin reversed the pulmonary 
alterations caused by TSC2-/- ASM cell administration [23]. In this case 
the two agents had similar effects in reducing the number and, likely, 
the infiltration of LAM/TSC cells in uterus.
Uterine LAM lesions in sporadic LAM patients have abundance of 
lymphatic endothelial cells compared to those of TSC-LAM patients 
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Figure 4: Analysis of lymphatic vessels in uterus sections after LAM/TSC cell 
administration. Representative images of uterus sections showing labelling of 
lymphatic capillary marker LYVE-1 (green) in control mice (A), in LAM/TSC 
cell-administered mice (B), in LAM/TSC cell-administered mice treated with 
anti-EGFR antibody (C) and in LAM/TSC cell-administered mice treated with 
rapamycin (D) (X5). Nuclei of cells are stained with DAPI (blue). Scale bars: 
400µm. Quantification of lymphatic vessels in uteri was calculated as LVD in 
five fields for each mouse (E). Data are expressed as mean ±SEM.
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suggesting an important and specific role for lymphangiogenesis in 
the progression of uterine lesions in sporadic LAM [9]. In our model, 
angiogenesis was increased in uteri after LAM/TSC administration 
while lymphangiogenesis remained unchanged. The increased number 
of blood vessels is related to LAM/TSC cell administration suggesting 
that in uteri of our mouse model the haematological circulatory system 
might be preferred to lymphatic system for migration and LAM /TSC 
cell infiltration may cause the promotion of blood vessel formation. The 
treatment with rapamycin and anti-EGFR antibody caused a reduction 
of the number of blood vessels that became similar to the control.  
LAM cell clusters enveloped by lymphatic endothelial cells have 
been identified in LAM lesions that express lymphatic endothelial 
markers such as VEGFR-3, podoplanin, and prox-1 and VEGF-D is 
elevated in serum of LAM patients correlating with the severity of 
the disease [37]. However, in our model LYVE 1 positivity in uteri 
did not differ in quantitative expression between the groups while it 
changed in localization. In control and LAM/TSC cell-administered-
mice LYVE 1 lymphatic vessel profile was within the myometrial 
circular and longitudinal muscle layers while after the administration 
of rapamycin and anti-EGFR antibody, immunoreactivity was mainly 
localized in the perimetrium. Thus both treatments affected lymphatic 
vessel distribution in uteri while they were effective in the control of 
lymphangiogenesis in lungs in our previous mouse model developed 
with the administration of TSC2-/- ASM cells [23].
These data regarding angiogenesis and lymphangiogenesis differ 
from what we previously observed in lungs by administration of 
TSC2-/- ASM cells [24]. In that case lung lesions were accompanied by 
an increase of lymphangiogenesis markers such as the expression of 
LYVE 1 and the levels of VEGF in serum and lung tissues [24]. On 
the contrary, angiogenesis was not altered in any experimental group. 
These differences might be due to the tissue characteristics, lung and 
uterus, and to the route of administration that favours the invasion of 
lungs. 
In conclusion our data describe the ability of LAM/TSC cells to 
migrate and invade uteri such as benign cancer cells without causing 
any morphological alteration. In this model the administration of 
human cells increased the number of blood vessels while surprisingly 
lymphangiogenesis seems unaffected. Anti-EGFR antibody and 
rapamycin treatments confirm their therapeutic potential by reducing 
the number of human LAM/TSC cells and normalizing the number of 
blood vessels. Thus these data support the therapeutic value of anti-
EGFR antibody and rapamycin in controlling ASM cell invasion in 
TSC and LAM patients.
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